ARBUTUS BIOPHARMA CORP (ABUS) Stock Balance Sheet
USA - NASDAQ:ABUS - CA03879J1003 - Common Stock
4.525 USD
+0.01 (+0.11%)
| MRQ (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | null | null | null | null | null | |||
| Cash Equivalents | 37.41M | 36.33M | 26.29M | 30.80M | 109.30M | |||
| Cash Due From Banks | null | null | null | null | null | |||
| Investments | null | null | null | null | null | |||
| Net Loans | null | null | null | null | null | |||
| Insurance Receivables | null | null | null | null | null | |||
| Marketable Securities | 60.68M | 86.29M | 99.72M | 116.10M | 46.00M | |||
| Receivables | 1.02M | 2.41M | 1.78M | 1.40M | 900.00K | |||
| Inventories | null | null | null | null | null | |||
| Other Current Assets | 4.01M | 2.28M | 4.25M | 2.90M | 4.40M | |||
| Total Current Assets | 103.12M | 127.32M | 132.03M | 151.10M | 160.70M | |||
| Non-Current Assets | ||||||||
| PPE Net | 148.00K | 4.36M | 6.09M | 6.80M | 8.10M | |||
| Investments And Advances | null | 0 | 6.28M | 37.40M | 35.70M | |||
| Goodwill | null | null | null | null | null | |||
| Intangibles | null | null | null | null | null | |||
| Other Non-Current Assets | 0 | 34.00K | 0 | 100.00K | 100.00K | |||
| Total Non-Current Assets | 148.00K | 4.39M | 12.37M | 44.30M | 43.80M | |||
| TOTAL ASSETS | 103.27M | 131.71M | 144.40M | 195.40M | 204.50M | |||
| LIABILITIES | ||||||||
| Total Deposits | null | null | null | null | null | |||
| Current Liabilities | ||||||||
| Short Term Borrowings | null | null | null | null | null | |||
| Short Term Debt | 0 | 0 | 0 | 0 | 0 | |||
| Current Portion Of LT Debt. | null | null | null | null | null | |||
| Accrued Expenses | 2.93M | 5.73M | 7.47M | 12.90M | 8.00M | |||
| Accounts Payable | 1.32M | 2.32M | 3.22M | 3.50M | 3.20M | |||
| Other Current Liabilities | 768.00K | 7.57M | 11.79M | 16.50M | 0 | |||
| Total Current Liabilities | 5.02M | 15.62M | 22.49M | 32.90M | 11.20M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0 | 0 | 0 | 0 | 0 | |||
| Deferred Taxes/Income | null | null | null | null | null | |||
| Other Non-Current Liabilities | 15.27M | 18.72M | 15.90M | 25.70M | 23.80M | |||
| Total Non-Current Liabilities | 15.27M | 18.72M | 15.90M | 25.70M | 23.80M | |||
| TOTAL LIABILITIES | 20.29M | 34.34M | 38.38M | 58.60M | 35.00M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.37B | -1.35B | -1.28B | -1.20B | -1.13B | |||
| Additional Paid In Capital | 82.63M | 82.05M | 81.27M | 72.40M | 65.50M | |||
| Minority Interest | null | null | null | null | null | |||
| Common Shares | 1.42B | 1.41B | 1.35B | 1.32B | 1.29B | |||
| Treasury Stock | null | null | null | null | null | |||
| Other Shareholders' Equity | -48.19M | -48.13M | -48.42M | -50.50M | -48.30M | |||
| Shares Outstanding | 191.64M | 189.96M | 169.87M | 157.50M | 145.00M | |||
| Tangible Book Value per Share | 0.433 | 0.5125 | 0.6241 | 0.8692 | 1.1683 | |||
| Total Shareholders' Equity | 82.98M | 97.37M | 106.02M | 136.90M | 169.40M | |||
| TOTAL LIABILITIES AND EQUITY | 103.27M | 131.71M | 144.40M | 195.40M | 204.50M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 20.53 | 8.15 | 5.87 | 4.59 | 14.35 | |||
| Return On Assets (ROA) | -52.54% | -53.09% | -50.45% | -35.55% | -43.22% | |||
| Return On Equity (ROE) | -65.38% | -71.81% | -68.71% | -50.74% | -52.18% | |||
All data in USD , ROIC based on taxRate of 0.21